Education
About Us
Working with TipRanks
Follow Us
Palvella Therapeutics, Inc. (PVLA)
:PVLA
PVLA Analyst Ratings
Strong Buy
10 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
PVLA Stock 12 Month Forecast
Average Price Target
$58.33
▲(26.53% Upside)
| Highest Price Target$90.00 | Average Price Target$58.33 | Lowest Price Target$38.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
TD Cowen
$44→$65
Buy
41.00%
Upside
Reiterated
08/15/25
Palvella Therapeutics: Strong Financial Position and Clinical Progress Justify Buy Rating with Raised Price TargetWe are raising our target to $65. 2Q25 Financials Update PVLA reported a 2Q25 net loss of ~$9.5M and LPS of ($0.86). 2Q25 R&D and G&A expenses were $5.1M (+26% q/q) and $4.1M (+9% q/q), respectively. PVLA ended 2Q25 with $70.4M cash and reiterated guidance for FY25 cash burn of ~$30M. Mgmt still estimates current cash should provide runway into 2H27 and cover 1) the full Ph3 SELVA MLM trial, 2) the full Ph2 TOIVA CVM trial, 3) MLM NDA submission and pre-commercialization efforts, and 4) clinical trial initiations for a new QTORIN rapa indication and a new QTORIN product candidate (discussed below).
H.C. Wainwright
$38→$75
Buy
62.69%
Upside
Reiterated
08/15/25
Truist Financial
―
Buy
―
Reiterated
08/15/25
Chardan Capital
$50→$60
Buy
30.15%
Upside
Reiterated
08/14/25
LifeSci Capital
$90
Buy
95.23%
Upside
Reiterated
08/14/25
JonesTrading
$45→$56
Buy
21.48%
Upside
Reiterated
08/14/25
Stifel Nicolaus
$45→$60
Buy
30.15%
Upside
Reiterated
08/14/25
Raymond James
$54
Buy
17.14%
Upside
Initiated
08/06/25
Scotiabank
$50
Buy
8.46%
Upside
Reiterated
07/22/25
Canaccord Genuity
$52
Buy
12.80%
Upside
Reiterated
06/23/25
TR | OpenAI - 4o
―
Hold
―
Upgraded
04/11/25
Cantor Fitzgerald
$30→$70
Buy
51.84%
Upside
Reiterated
03/31/25
Lucid Capital
$49
Buy
6.29%
Upside
Initiated
03/18/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
TD Cowen
$44→$65
Buy
41.00%
Upside
Reiterated
08/15/25
Palvella Therapeutics: Strong Financial Position and Clinical Progress Justify Buy Rating with Raised Price TargetWe are raising our target to $65. 2Q25 Financials Update PVLA reported a 2Q25 net loss of ~$9.5M and LPS of ($0.86). 2Q25 R&D and G&A expenses were $5.1M (+26% q/q) and $4.1M (+9% q/q), respectively. PVLA ended 2Q25 with $70.4M cash and reiterated guidance for FY25 cash burn of ~$30M. Mgmt still estimates current cash should provide runway into 2H27 and cover 1) the full Ph3 SELVA MLM trial, 2) the full Ph2 TOIVA CVM trial, 3) MLM NDA submission and pre-commercialization efforts, and 4) clinical trial initiations for a new QTORIN rapa indication and a new QTORIN product candidate (discussed below).
H.C. Wainwright
$38→$75
Buy
62.69%
Upside
Reiterated
08/15/25
Truist Financial
―
Buy
―
Reiterated
08/15/25
Chardan Capital
$50→$60
Buy
30.15%
Upside
Reiterated
08/14/25
LifeSci Capital
$90
Buy
95.23%
Upside
Reiterated
08/14/25
JonesTrading
$45→$56
Buy
21.48%
Upside
Reiterated
08/14/25
Stifel Nicolaus
$45→$60
Buy
30.15%
Upside
Reiterated
08/14/25
Raymond James
$54
Buy
17.14%
Upside
Initiated
08/06/25
Scotiabank
$50
Buy
8.46%
Upside
Reiterated
07/22/25
Canaccord Genuity
$52
Buy
12.80%
Upside
Reiterated
06/23/25
TR | OpenAI - 4o
―
Hold
―
Upgraded
04/11/25
Cantor Fitzgerald
$30→$70
Buy
51.84%
Upside
Reiterated
03/31/25
Lucid Capital
$49
Buy
6.29%
Upside
Initiated
03/18/25
Best Analysts Covering Palvella Therapeutics
1 Month
xxx
Success Rate
5/5 ratings generated profit
Average Return
+26.56%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 100.00% of your transactions generating a profit, with an average return of +26.56% per trade.
3 Months
xxx
Success Rate
5/6 ratings generated profit
Average Return
+79.52%
reiterated a xxx
rating 23 hours ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 83.33% of your transactions generating a profit, with an average return of +79.52% per trade.
1 Year
Success Rate
6/6 ratings generated profit
Average Return
+172.83%
reiterated a buy rating 23 hours ago
Copying Andrew Fein's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +172.83% per trade.
2 Years
xxx
Success Rate
6/6 ratings generated profit
Average Return
+172.83%
reiterated a xxx
rating 23 hours ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +172.83% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
PVLA Analyst Recommendation Trends
Rating
Apr 25
May 25
Jun 25
Jul 25
Aug 25
Strong Buy
20
21
16
10
6
Buy
0
0
0
2
6
Hold
1
1
1
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
21
22
17
12
12
Each month's total comprises the sum of three months' worth of ratings.
PVLA Financial Forecast
PVLA Stock Forecast FAQ
What is PVLA’s average 12-month price target, according to analysts?
Based on analyst ratings, Palvella Therapeutics, Inc.’s 12-month average price target is 58.33.
What is PVLA’s upside potential, based on the analysts’ average price target?
Palvella Therapeutics, Inc. has 26.53% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is PVLA a Buy, Sell or Hold?
Palvella Therapeutics, Inc. has a consensus rating of Strong Buy which is based on 10 buy ratings, 0 hold ratings and 0 sell ratings.
What is Palvella Therapeutics, Inc.’s price target?
The average price target for Palvella Therapeutics, Inc. is 58.33. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $90.00 ,the lowest forecast is $38.00. The average price target represents 26.53% Increase from the current price of $46.1.
The highest analyst price target is $90.00 ,the lowest forecast is $38.00. The average price target represents 26.53% Increase from the current price of $46.1.
What do analysts say about Palvella Therapeutics, Inc.?
Palvella Therapeutics, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.
How can I buy shares of PVLA?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.